DAL OUTCOMES TRIAL WITH DALCETRAPIB IN PATIENTS WITH ACS AND T2DM.

Dear my friends and fellow Colleagues, Here is an update on DAL Outcomes Trial done with Dalcetrapib. DAL OUTCOMES TRIAL Patients with a recent Acute Coronary Syndrome, ACS with incident diabetes is and is reduced substantially by treatment with Dalcetrapib. Reference Schwartz G et al, Diabetes Care 2020 May; 43(5): 1077-1084. Regards and thanks, Dr Sepuri Krishna Mohan.

3 Likes

LikeAnswersShare
Sir unaware of this molecule If iam right is it antiplatelets Thanx for updates
Dear Sir, Dalcetrapib is a Cholesterol Lowering Drug which acts by inhibiting the CETP, Cholesteryl Ester Transfer Protein. This increases HDLC sir. This is a very Cardiovascular friendly drug. It's a product of ROCHE. This molecule is especially useful in ACS with T2DM, thereby reduces CV morbidity and mortality. Daily dose is 600 mg. Regards and thanks, Dr Sepuri Krishna Mohan.
0

Cases that would interest you